How were new medicines discovered?
The DOI matches its Crossref record; 171 of the 173 references it cites were found in a registry or an index.
Abstract
Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are two main advantages of the phenotypic screening method for identifying covalent PPI inhibitors. Firstly, this technique identifies cell-active compounds directly. Secondly, the biological target does not have to be known before screening [81].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [81]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Research works printed but not linked: 3
- Cuppoletti J. et al. Recombinant and native intestinal cell ClC-2 Cl− channels are activated by RU-0211. Gastroenterology 122, A538 (2002).
- Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
- Mendel, D. B. et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Cited by
Items 901–1,000 of 1,000
Muthusamy, V., Ariën, K. K., Heeres, J., Joossens, J., Dirié, B., Lyssens, S., Míchiels, J., Cos, P., Lewi, P. J., Vanham, G., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.08.005 · Cited by 15
Chen, J., Kassenbrock, A. R., Li, B. X., & Xiao, X. (2013) · MedChemComm · doi:10.1039/c3md00134b · Cited by 15
Regenerative Medicine: Transforming the Drug Discovery and Development ParadigmPreprint
Karathanasis, S. K. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014084 · Cited by 15
Future Viable Models of Psychiatry Drug Discovery in Pharma
Rizzo, S. J. S., Edgerton, J. R., Hughes, Z. A., & Brandon, N. J. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113475871 · Cited by 14
Ye, T., Selvaraju, M., & Sun, C. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b01224 · Cited by 14
Identification of radiation‐induced EndMT inhibitors through cell‐based phenomic screening
Song, Y., Lee, S., Kim, A., Kim, S., Heo, J., Shum, D., Kim, S., Choi, I., Lee, Y., & Seo, H. R. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12552 · Cited by 18
Salame, N., Fooks, K., El-Hachem, N., Bikorimana, J., Mercier, F., & Rafei, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.852143 · Cited by 18
Wang, Q., Zhang, X., Li, Q., Liu, X., Huang, Y., Cheng, S., Shinohara, H., Liu, Z., & Zhu, X. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.135286 · Cited by 15
Chen, X., Niu, X., Li, L., Chen, K., Song, D., Chen, B., Yang, S., & Wu, Z. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c09267 · Cited by 14
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Lucas‐Hourani, M., Munier‐Lehmann, H., Helynck, O., Komarova, A. V., Desprès, P., Tangy, F., & Vidalain, P. (2014) · Journal of Visualized Experiments · doi:10.3791/51222 · Cited by 18
Biological Networks and Drug Discovery—Where Do We Stand?
Geppert, T., & Koeppen, H. (2014) · Drug Development Research · doi:10.1002/ddr.21207 · Cited by 16
Singh, R., Beasley, R., Long, T., & Caffrey, C. R. (2016) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2016.2550444 · Cited by 15
Zaini, M. A., Müller, C., Ackermann, T., Reinshagen, J., Kortman, G., Pleß, O., & Calkhoven, C. F. (2017) · Scientific Reports · doi:10.1038/srep42603 · Cited by 15
Kunimoto, R., Dimova, D., & Bajorath, J. (2017) · ACS Omega · doi:10.1021/acsomega.7b00215 · Cited by 14
Ha, J.-E., Yang, S., & Gong, Y. (2018) · ACS Combinatorial Science · doi:10.1021/acscombsci.7b00174 · Cited by 14
Eldik, L. J. V., Sawaki, L. A., Bowen, K., Laskowitz, D. T., Noveck, R. J., Hauser, B., Jordan, L., Spears, T. G., Wu, H., Watt, K., et al. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.795 · Cited by 15
Quancard, J., Bach, A., Cox, B. J., Craft, R., Finsinger, D., Guéret, S. M., Hartung, I. V., Laufer, S., Messinger, J., Sbardella, G., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100041 · Cited by 15
Ring Distortion of Vincamine Leads to the Identification of Re-Engineered Antiplasmodial Agents
Norwood, V. M., Murillo-Solano, C., Goertzen, M. G., Brummel, B. R., Perry, D. L., Rocca, J. R., Chakrabarti, D., & Huigens, R. W. (2021) · ACS Omega · doi:10.1021/acsomega.1c02480 · Cited by 15
Stingray Venom Proteins: Mechanisms of Action Revealed Using a Novel Network Pharmacology Approach
Kirchhoff, K. N., Billion, A., Voolstra, C. R., Kremb, S., Wilke, T., & Vilcinskas, A. (2021) · Marine Drugs · doi:10.3390/md20010027 · Cited by 14
Park, Y. M., Dahlem, C., Meyer, M. R., Kiemer, A. K., Müller, R., & Herrmann, J. E. (2022) · Molecules · doi:10.3390/molecules27041290 · Cited by 14
In silico Drug Screening Approach Using L1000-Based Connectivity Map and Its Application to COVID-19
Asano, T., Chelvanambi, S., Decano, J. L., Whelan, M. C., Aïkawa, E., & Aikawa, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.842641 · Cited by 14
Park, J., Oh, S., & Park, S. B. (2012) · Angewandte Chemie · doi:10.1002/ange.201200609 · Cited by 14
Yang, S., Shen, T., Fang, Y., Wang, X., Zhang, J., Yang, W., Huang, J., & Han, X. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.12.007 · Cited by 16
A High Content Screening Approach to Identify Molecules Neuroprotective for Photoreceptor Cells
Fuller, J. A., Shaw, G. C., Wersinger, D. M. B., Hansen, B. S., Berlinicke, C. A., Inglese, J., & Zack, D. J. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3209-8_97 · Cited by 14
An Exploratory Evaluation of Tyrosine Hydroxylase Inhibition in Planaria as a Model for Parkinsonism
Prokai, D., Nguyen, T., Kamrowski, K., Chandra, A., Talamantes, T., Baxter, L., & Prókai, L. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141223289 · Cited by 14
High Content Screening as High Quality Assay for Biological Evaluation of Photosensitizers In Vitro
Vaz, G. M. F., Paszko, E., Davies, A. M., & Senge, M. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070653 · Cited by 14
Search for Anti-angiogenic Substances from Natural Sources
Kotoku, N., Arai, M., & Kobayashi, M. (2016) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c15-00744 · Cited by 14
Studying human disease using human neurons
Ahfeldt, T., Litterman, N. K., & Rubin, L. L. (2016) · Brain Research · doi:10.1016/j.brainres.2016.03.051 · Cited by 18
Anti-tubercular drug discovery: in silico implications and challenges
Mehra, R., Khan, I. A., & Nargotra, A. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.028 · Cited by 14
The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery
Segatto, N. V., Remião, M. H., Schachtschneider, K. M., Seixas, F. K., Schook, L. B., & Collares, T. V. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00894 · Cited by 16
Sabatier, P., Saei, A. A., Wang, S., & Zubarev, R. A. (2018) · PROTEOMICS · doi:10.1002/pmic.201800118 · Cited by 14
Jörg, M., & Madden, K. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00022e · Cited by 15
Bush, J. A., Williams, C. C., Meyer, S. M., Tong, Y., Haniff, H. S., Childs‐Disney, J. L., & Disney, M. D. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00014 · Cited by 14
Future Directions in Pain Management
Pleticha, J., Maus, T. P., & Beutler, A. S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.02.015 · Cited by 16
Toviwek, B., Suphakun, P., Choowongkomon, K., Hannongbua, S., & Gleeson, M. P. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.08.063 · Cited by 14
Martín‐Escolano, R., Marı́n, C., Vega, M., Martín‐Montes, Á., Medina‐Carmona, E., López, C., Rotger, C., Costa, A., & Sánchez‐Moreno, M. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.01.033 · Cited by 14
Perkins, K. R., Atilho, R. M., Moon, M. H., & Breaker, R. R. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00713 · Cited by 14
High-throughput screening and structure-based approaches to hit discovery: is there a clear winner?
Jhoti, H., Rees, S., & Solari, R. C. E. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.857654 · Cited by 15
Liu, B. H. M., Lin, Y., Long, X., Hung, S. W., Gaponova, A. V., Ren, F., Zhavoronkov, A. A., Pun, F. W., & Wang, C. C. (2024) · Advanced Science · doi:10.1002/advs.202406565 · Cited by 27
Ogbodo, J. O., Egba, S. I., Ikechukwu, G. C., Paul, P. C., Mba, J. O., Ugwu, O. P.-C., & Ezike, T. C. (2025) · Processes · doi:10.3390/pr13010154 · Cited by 13
Human pluripotent stem cells on artificial microenvironments: a high content perspective
Viswanathan, P., Gaskell, T. L., Moens, N., Culley, O. J., Hansen, D. M., Gervasio, M. K. R., Yeap, Y. J., & Danovi, D. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00150 · Cited by 14
Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins
Sahm, B. D. B., Peres, J., Teixeira, P. R., dos Santos, E. A., Branco, P. C., Bauermeister, A., Kimani, S., Moreira, E. A., Bisi-Alves, R., Bellis, C., et al. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00110 · Cited by 13
ADMET analysis of phyto-components of Syzygium cumini seeds and Allium cepa peels
Kadri, H. S., & Minocheherhomji, F. P. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00136-9 · Cited by 13
Diósdi, Á., Hirling, D., Kovács, M., Tóth, T., Harmati, M., Koós, K., Buzás, K., Piccinini, F., & Horváth, P. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.040 · Cited by 18
The Global Research Trend in Electrochemical Microfluidic Technology: A Bibliometric Review
Zhang, X., Zhang, Y., Guo, W., Jiao, S., & Liu, X. (2022) · Chemosensors · doi:10.3390/chemosensors11010014 · Cited by 14
Application of in Silico Technologies for Drug Target Discovery and Pharmacokinetic Analysis
Iwata, H. (2023) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c22-00638 · Cited by 15
On-DNA hydroalkylation of N -vinyl heterocycles via photoinduced EDA-complex activation
Sharique, M., Matsuo, B. T., Granados, A., Kim, S., Arshad, M., Oh, H., Wu, V. E., Huang, M., Csakai, A., Marcaurelle, L. A., et al. (2023) · Chemical Science · doi:10.1039/d3sc03731b · Cited by 14
Considerations of Protein Subpockets in Fragment‐Based Drug Design
Bartolowits, M. D., & Davisson, V. J. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12631 · Cited by 14
Determining Physical Principles of Subcellular Organization
Needleman, D., & Jan Brugués, A. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.04.018 · Cited by 14
Joseph, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809357-3.00009-6 · Cited by 13
Waters, N., Svensson, P., Kullingsjö, J., Pontén, H., Andreasson, T., Sunesson, Y., Ljung, E., Sonesson, C., & Waters, N. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00371 · Cited by 14
A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers
Okour, M., Derimanov, G. S., Barnett, R., Fernández, E., Ferrer, S. B., Gresham, S., Hossain, M. S., Gamo, F., Koh, G. C. K. W., Pereira, A. I., et al. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13476 · Cited by 13
Recent Advances in Drug Repurposing for Parkinson’s Disease
Chen, X., Gumina, G., & Virga, K. G. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180719144850 · Cited by 15
Ohnesorge, N., Sasore, T., Hillary, D., Álvarez, Y., Carey, M., & Kennedy, B. N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00508 · Cited by 14
Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity
Sameshima, T., Yukawa, T., Hirozane, Y., Yoshikawa, M., Katoh, T., Hara, H., Yogo, T., Miyahisa, I., Okuda, T., Miyamoto, M., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00128 · Cited by 14
Paape, D., Prendergast, C. T., Price, H. P., Doehl, J. S. P., & Smith, D. F. (2020) · Parasites & Vectors · doi:10.1186/s13071-020-3999-1 · Cited by 13
Korkor, C. M., Garnie, L. F., Amod, L., Egan, T. J., & Chibale, K. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob01730b · Cited by 13
Mathew, G., & Unnikrishnan, M. K. (2015) · Inflammation Research · doi:10.1007/s00011-015-0851-8 · Cited by 14
Cellular Assays for Drug Discovery in Genetic Disorders of Intracellular Trafficking
Matteis, M. A. D., Vicinanza, M., Venditti, R., & Wilson, C. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153415 · Cited by 17
Janero, D. R. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.925876 · Cited by 14
The human secretome – the proteins secreted from human cellsPreprint
Uhlén, M., Tegel, H., Sivertsson, Å., Kuo, C., Gutierrez, J. M., Lewis, N. E., Forsström, B., Dannemeyer, M., Fagerberg, L., Malm, M., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/465815 · Cited by 17
Advances of the Target-Based and Phenotypic Screenings and Strategies in Drug Discovery
Wang, S., Wang, Z., Fang, L., Lv, Y., & Du, G. (2022) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.v1i1.199 · Cited by 19
Traditional Chinese Medicine and Clinical Pharmacology
Marshall, A. C. (2020) · Springer eBooks · doi:10.1007/978-3-319-56637-5_60-2 · Cited by 12
Graph neural networks are promising for phenotypic virtual screening on cancer cell lines
Vishwakarma, S., Hernández-Hernández, S., & Ballester, P. J. (2024) · Biology Methods and Protocols · doi:10.1093/biomethods/bpae065 · Cited by 13
Medical Innovation Then and Now: Perspectives of Innovators Responsible for Transformative Drugs
Xu, S., & Kesselheim, A. S. (2014) · The Journal of Law Medicine & Ethics · doi:10.1111/jlme.12176 · Cited by 13
Schachter, B. (2012) · Nature Biotechnology · doi:10.1038/nbt.2385 · Cited by 12
A Quantitative Systems Pharmacology Perspective on Cancer Immunology
Byrne-Hoffman, C. N. N., & David, I. I. (2015) · Processes · doi:10.3390/pr3020235 · Cited by 12
Discovery of Modulators of Adipocyte Physiology Using Fully Functionalized Fragments
Galmozzi, A., Parker, C. G., Kok, B. P., Cravatt, B. F., & Sáez, E. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7847-2_9 · Cited by 12
An in silico Approach for Integrating Phenotypic and Target‐based Approaches in Drug Discovery
Iwata, H., Kojima, R., & Okuno, Y. (2019) · Molecular Informatics · doi:10.1002/minf.201900096 · Cited by 13
Glycohybrid molecules in medicinal chemistry: Present status and future prospective
Kumari, P., Narayana, C., Tiwari, G., & Sagar, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816675-8.00011-7 · Cited by 14
Multi-Institution Research and Education Collaboration Identifies New Antimicrobial Compounds
Fuller, A. A., Dounay, A. B., Schirch, D. M., Rivera, D. G., Hansford, K. A., Elliott, A. G., Zuegg, J., Cooper, M. A., Blaskovich, M. A. T., Hitchens, J. R., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00732 · Cited by 12
Improving Translational Paradigms in Drug Discovery and Development
Williams, M. J. (2021) · Current Protocols · doi:10.1002/cpz1.273 · Cited by 12
Lee, H., Lacbay, C. M., Boutin, R., Matralis, A. N., Park, J., Waller, D. D., Guan, T. L., Sébag, M., & Tsantrizos, Y. S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01913 · Cited by 12
Sakai, T. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108234 · Cited by 13
Choi, S. Y. C., Ribeiro, C. F., Wang, Y. Z., Loda, M. F., Plymate, S. R., & Uo, T. (2022) · Biomolecules · doi:10.3390/biom12111590 · Cited by 13
Feng, Z., Zhu, S., Li, W., Yao, M., Song, H. L., & Wang, R. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114867 · Cited by 12
Ilg, M. M., Lapthorn, A. R., Ralph, D. J., & Cellek, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277646 · Cited by 12
Desroches‐Castan, A., Quélard, D., Demeunynck, M., Constant, J., Dong, C., Kéramidas, M., Coll, J., Barette, C., Lafanéchère, L., & Feige, J. (2015) · Oncotarget · doi:10.18632/oncotarget.2979 · Cited by 12
The Role of Historical Bioactivity Data in the Deconvolution of Phenotypic Screens
Bornot, A., Blackett, C., Engkvist, O., Murray, C. M., & Bendtsen, C. (2014) · SLAS DISCOVERY · doi:10.1177/1087057113518966 · Cited by 12
Kotoku, N., Nakata, C., Kawachi, T., Sato, T., Guo, X., Ito, A., Sumii, Y., Arai, M., & Kobayashi, M. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.026 · Cited by 12
Kernéis, S. M., Swift, L. H., Lewis, C. W., Bruyère, C., Oumata, N., Colas, P., Ruchaud, S., Bain, J. F., & Golsteyn, R. M. (2014) · Natural Product Research · doi:10.1080/14786419.2014.979423 · Cited by 12
Novel Therapeutic Approaches for Neglected Infectious Diseases
Martín‐Plaza, J. J., & Chatelain, E. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114559907 · Cited by 12
Recent advances in technologies for developing drugs againstChlamydia pneumoniae
Hanski, L. L., & Vuorela, P. M. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.915309 · Cited by 12
Tubulin is a molecular target of the Wnt-activating chemical probe
Fukuda, Y., Sano, O., Kazetani, K., Yamamoto, K., Iwata, H., & Matsui, J. (2016) · BMC Biochemistry · doi:10.1186/s12858-016-0066-9 · Cited by 12
Whitlon, D. S. (2016) · Hearing Research · doi:10.1016/j.heares.2016.07.019 · Cited by 12
Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors
Buchynskyy, A., Gillespie, J. R., Hulverson, M. A., McQueen, J., Creason, S. A., Ranade, R. M., Duster, N. A., Gelb, M. H., & C, F. S. B. A. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.019 · Cited by 12
Ma, L., Xu, Y., Wei, Z., Xin, G., Xing, Z., Niu, H., & Huang, W. Q. (2017) · Scientific Reports · doi:10.1038/s41598-017-05416-8 · Cited by 12
Ghods, A., Gilbert, J., Baker, J. R., Russell, C. C., Sakoff, J. A., & McCluskey, A. (2018) · Royal Society Open Science · doi:10.1098/rsos.171189 · Cited by 12
Carta, D., Brun, P., Prà, M. D., Bernabé, G., Castagliuolo, I., & Ferlin, M. G. (2018) · MedChemComm · doi:10.1039/c8md00139a · Cited by 12
Introduction to biological complexity as a missing link in drug discovery
Gintant, G. A., & George, C. H. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1480608 · Cited by 12
Feng, H., Li, C.-P., Shu, S., Liu, H., & Zhang, H. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0028-4 · Cited by 12
Target Identification Using Chemical Probes
Moustakim, M., Felce, S. L., Zaarour, N., Farnie, G., McCann, F. E., & Brennan, P. E. (2018) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2018.09.013 · Cited by 14
Naughton, S. X., Beck, W. D., Wei, Z., Wu, G., & Terry, A. V. (2020) · Toxicology · doi:10.1016/j.tox.2020.152379 · Cited by 14
Vauquelin, G., Liefde, I. V., & Swinney, D. C. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.09.001 · Cited by 13
Self-citationCell-based and virtual fragment screening for adrenergic α2C receptor agonists
Szőllősi, E., Bobok, A. Á., Kiss, L., Vass, M., Kurkó, D., Kolok, S., Visegrády, A., & Keserű, G. M. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.013 · Cited by 12
Orphan diseases: state of the drug discovery art
Volmar, C., Wahlestedt, C., & Brothers, S. P. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-015-0423-0 · Cited by 12
A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
Fouda, A. E., Tahsini, M., Khodayarian, F., Al-nafisah, F., & Rafei, M. (2017) · Journal of Visualized Experiments · doi:10.3791/55199 · Cited by 14
Distinct in vivo target occupancy by bivalent‐ and induced‐fit‐like binding drugs
Vauquelin, G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13989 · Cited by 12
Requirements for Using iPSC-Based Cell Models for Assay Development in Drug Discovery
Christensen, K., Roudnicky, F., Patsch, C., & Burcin, M. M. (2017) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2017_23 · Cited by 14
Solana‐Manrique, C., Moltó, M. D., Calap-Quintana, P., Sanz, F., Llorens, J. V., & Paricio, N. (2019) · Springer eBooks · doi:10.1007/978-981-13-2218-1_15 · Cited by 16
Metadata
- Authors
- Swinney, D. C., & Anthony, J.
- Corresponding author
- Swinney, David C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-06-24
- Volume
- 10
- Issue
- 7
- Pages
- 507-519
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2052214665
- Cited by
- 1,812
- References
- 173
- Citations by year
- 2026: 80 · 2025: 73 · 2024: 102 · 2023: 86 · 2022: 96 · 2021: 109 · 2020: 127 · 2019: 129 · 2018: 113 · 2017: 136 · 2016: 160 · 2015: 170 · 2014: 157 · 2013: 137 · 2012: 115
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug discovery strategies, phenotypic screening, target-based screening, molecular mechanisms of action, first-in-class drugs, new chemical entities, small molecule drugs, drug attrition, FDA-approved drugs
- MeSH terms
- Pharmacological Phenomena, Drug Industry, Drug Evaluation, Preclinical, Humans, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Drug Discovery, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.